Nektar Therapeutics Analyst Price Targets

Nektar Therapeutics

NKTRNASDAQ

Trade with Public

$36.64

0.862.4%

最終更新: Oct 19, 4:00 PM

$36.64

0.862.4%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Nektar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nektar Therapeutics (NKTR).

Price Target Range — 11 Quarters

Analyst Consensus — 14 Analysts

10Buy

4Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$121Upside to Avg. PT+231.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Neutral	$53
Oct 12, 2026	Leerink Partners	Will Soghikian	Initiate	Outperform	$130
Oct 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Oct 9, 2026	Raymond James	Thomas Deal	Initiate	Market Perform	—
Oct 2, 2026	HC Wainwright & Co.	Arthur He	Maintained	Buy	$185
Sep 28, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Sep 25, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Sep 23, 2026	Wedbush	Martin Fan	PT Cut	Neutral	$80→$50
Sep 16, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Sep 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Aug 21, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$65
Jul 22, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$153
May 11, 2026	Wedbush	Martin Fan	PT Cut	Neutral	$95→$80
May 8, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$105→$192
Apr 21, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$123→$151
Apr 21, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$70→$95
Apr 20, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$165→$185
Apr 20, 2026	BTIG	Julian Harrison	PT Raise	Buy	$151→$178
Mar 24, 2026	Wedbush	Martin Fan	Initiate	Neutral	$70
Mar 17, 2026	TD Cowen	Marc Frahm	Initiate	Buy	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.

Benzinga Newsdesk

PRO
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.

Benzinga Newsdesk

Nektar Therapeutics

Nektar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

PRO
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRO
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

PRO
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

ニュース

パートナーシップ

ベンジンガ・グローバル

Nektar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

PRO
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRO
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

PRO
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

People Also Watch

People Also Watch

Nektar Therapeutics

Nektar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

PROLeerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

PROBTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRORaymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

PROHC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

PROBTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

ニュース

パートナーシップ

ベンジンガ・グローバル

Nektar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

PROLeerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

PROBTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRORaymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

PROHC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

PROBTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

PRO
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRO
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

PRO
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRO
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

PRO
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

PRO
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

PRO
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target